Neurology
Remibrutinib Demonstrates Superior Efficacy and Safety over Teriflunomide in Relapsing Multiple Sclerosis: Insights from REMODEL-1 and REMODEL-2 Phase 3 Trials
Two phase 3 trials establish remibrutinib, a BTK inhibitor, as more effective and better tolerated than teriflunomide in relapsing multiple sclerosis, supporting its potential as a new oral treatment.
